ArticleRheumatology (Oxford, England)2020
The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients.
Article in Rheumatology (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05391100 (Screening of Patients With Rheumatoid Arthritis for Interstitial Lung Disease With Radiographic and Labor Methods), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Screening of Patients With Rheumatoid Arthritis for Interstitial Lung Disease With Radiographic and Labor Methods
Who cites it
21 citing papers in PubMed, 56 citations in OpenAlex.
- Molecular imaging of fibroblast activation in systemic sclerosis using [European journal of nuclear medicine and molecular imaging · 2026Article
- Personalized Medicine for Systemic Sclerosis-Associated Interstitial Lung Disease.Current treatment options in rheumatology · 2025Article
- GLUT and FAPα as molecular markers for interstitial lung disease in systemic sclerosis.Respiratory research · 2025Article
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Molecular Imaging of Pulmonary Fibrosis.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Review
- QuantitativeArthritis research & therapy · 2024Article
- Fibroblast activation protein inhibitor PET/CT as an emerging diagnostic modality in interstitial lung disease and other fibrotic conditions.Rheumatology and immunology research · 2024Article
- Radiology of fibrosis. Part I: Thoracic organs.Journal of translational medicine · 2024Review
- Article
- Initial results with [European journal of nuclear medicine and molecular imaging · 2024Article
- Systemic sclerosis interstitial lung disease: unmet needs and potential solutions.Nature reviews. Rheumatology · 2024Review
- Recent innovations in the screening and diagnosis of systemic sclerosis-associated interstitial lung disease.Expert review of clinical immunology · 2023Review
- [Value of CT and transthoracic lung ultrasound in patients with systemic sclerosis : Joint statement of the ÖRG/ÖGP/ÖGR/ÖGUM].Zeitschrift fur Rheumatologie · 2022Review
- PET/CT and inflammatory mediators in systemic sclerosis-associated interstitial lung disease.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2022Article
- Positron Emission Tomography to Improve Assessment of Interstitial Lung Disease in Patients With Systemic Sclerosis Eligible for Autologous Stem Cell Transplantation.Frontiers in immunology · 2022Article
- The lungs were on fire: a pilot study ofArthritis research & therapy · 2021Article
- Engineering Advanced In Vitro Models of Systemic Sclerosis for Drug Discovery and Development.Advanced biology · 2021Review
- Article
- Novel Imaging Strategies in Systemic Sclerosis.Current rheumatology reports · 2020Review
- The race against time to disclose lung inflammation in interstitial lung disease in systemic sclerosis: is PET scan the winning solution?Rheumatology (Oxford, England) · 2020Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe reversibility of interstitial lung disease (ILD) in SSc is difficult to assess by current diagnostic modalities and there is clinical need for imaging techniques that allow for treatment stratification and monitoring. 18F-Fluorodeoxyglucose (FDG) PET/CT scanning may be of interest for this purpose by detection of metabolic activity in lung tissue. This study aimed to investigate the potential role of 18F-FDG PET/CT scanning for the quantitative assessment of SSc-related active ILD.
methods18F-FDG PET/CT scans and high resolution CT scans of eight SSc patients, including five with ILD, were analysed. For comparison, reference groups were included: eight SLE patients and four primary Sjögren's syndrome (pSS) patients, all without ILD. A total of 22 regions of interest were drawn in each patient at apical, medial and dorsobasal lung levels. 18F-FDG uptake was measured as mean standardized uptake value (SUVmean) in each region of interest. Subsequently, basal/apical (B/A) and medial/apical (M/A) ratios were calculated at patient level (B/A-p and M/A-p) and at tissue level (B/A-t and M/A-t).
resultsSUVmean values in dorsobasal ROIs and B/A-p ratios were increased in SSc with ILD compared with SSc without ILD (P = 0.04 and P = 0.07, respectively), SLE (P = 0.003 and P = 0.002, respectively) and pSS (P = 0.03 and P = 0.02, respectively). Increased uptake in the dorsobasal lungs and increased B/A-t ratios corresponded to both ground glass and reticulation on high resolution CT.
conclusionSemi-quantitative assessment of 18F-FDG PET/CT is able to distinguish ILD from non-affected lung tissue in SSc, suggesting that it may be used as a new biomarker for SSc-ILD disease activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.